My brother always said to me that the float was so
Post# of 7805
It’s all based on its outstanding shares, irs market cap, revenues, it’s product and competition, is it a product sold domestically or globally and the sector that the stock is trading in.
The biotech sector is a very risky investment to gamble in, but the risk rewards could be “HUGE” !!!!
I’ve seen some biotech stocks trade as high of over 50 times earnings.
My brother does like the product and said it does have potential.
The past year and half BIELS has finally changed BIG TIME and is about to enter the big leagues.
I need to correct you about Actipatch, it’s been BIELS product for the past 18 years that is a FDA approved pain relief device that is proven to work.
Biel now has a new and approve product device called RecoveryRx and it not only helps with pain relief but helps heal as well in the GLOBAL hospital surgical industry WORLDWIDE!!!
The last I can recall reading that there are over 500 million surgeries performed yearly globally.
You do the math and keep in mind BIELS is in a sector that can trade over 50 times earning.
Watch and see how quickly they build the gap on their outstanding shares.
Oh I forgot to mention as revenues roll in, possible buy back plan.
Oh yes I forgot one more think, how many shares are held by IBEX, Corp Officers and inside investors.
Don’t forget they have forgave loan interest the past few years.
Maybe depends on how many shares they hold, but they may just return some of their shares and shelve them.
Just a thought!!
GLTA!!